Pediatric Clinical Trials

The mission of the Pediatric Clinical Trials Research Program is to improve the health of the children of Kansas by building the Pediatric Department's capacity to participate in research on the next generation of diagnostic and therapeutic interventions being developed and evaluated for use in children.

Committee Members

• Prabhu Parimi , M.D., Chair
• Pam Shaw, M.D.
• James Casey, M.D.
• Ann Davis, Ph.D.
• Kathy Ellerbeck, M.D.
• Linda Schuck
• Nancy Stimpfel, RN

Contact Us

• Parbhu Parimi , M.D.
  Chair, Clinical Trials Committee
  pparimi@kumc.edu
  Phone: (913) 588-6377
  Pager: (913) 917-3288

 

Please note that new protocol submissions and re-submissions must be received by the submission deadline in order to be distributed to reviewers and be placed on the agenda for that month's meeting. Protocols and/or revisions received after the monthly submission deadline will be on the agenda for the following month's meeting.

Forms for Submissions:

• Clinical Trials Form
• Protocol Feasibility Checklist

These forms are in pdf format. You can complete them in Adobe Acrobat then print them out or e-mail them to Nancy Stimpfel. Alternatively, you can print out the blank form and complete it manualy.

For assistance, please contact:

Current Pediatric Clinical Trials:

• Casey, J.  (PI)  “The Genetics and Neurendocrinology of Short Stature International Study”
  Eli Lilly and Company
• Casey, J.  (PI) “Growth Hormone Study” Genentech Inc.
• Casey, J.  (PI) “Kabi International Growth Study” Pharmacia Upjohn
• Casey, J.  (PI) “Natural History Study Development of Type l Diabetes” NIH-TrialNet
• Casey, J.  (PI) “Patient registry for monitoring long term safety and efficacy of Increlex” Tercica Inc
• Harris, J (PI) “A Phase III, Randomized, Multinational Study, Double-Blinded for the Immunogenicity and Consistency Evaluation of 3 Hib-MenCy_TT Vaccine Lots in Healthy Infants 2, 4, 6, and 12 to 15 Months of Age” GlaxoSmithKline
• Harris, J (PI) “Immunogenicity and safety study of a booster dose of GSK Biological.  Meningococcal vaccine given at 12-15 months of age (co-administered with Pedvax HIB) or at 15-18 months of age (co-administered with Infanrix) in primed healthy toddlers.” GlaxoSmithKline
• Harris, J (PI) “Open Randomized, Multicenter Study of the Safety, Tolerability and Immunogenicity of VAQTA given concomitantly with PedvaxHIB and Infanrix in Healthy Children 15 months of age” Merck
• Harris, J. and Hetu, C. (Co-PI) “Effect of Rooibos Tea on Infant Colic” Children’s Miracle Network
• Lauer, Steve (PI) “Safety, Efficacy, and Pharmacokinetics of Lubiprostone in Pediatric Patients with Constipation” Sucampo
• Scotten, Mitzi (PI) “A Phase 3, International, multi-center, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease and FEV-1” Inspire Pharmaceuticals Inc.
• Sawyer, Tama (PI) “Surveillance of the RADARS 7 by Poison Control Centers” Denver Health and Hospital Authority
• Olson, N (PI) “Allergy Immunology Rheumatology” Pharmacia Corp
• Scheinman, Jon (PI) “Focal Glomenulosclerosis Trial” St. Joseph Hospital Medical Center
• Tancabelic, J  (PI) “Children’s Oncology Group” National Childhood Cancer Foundation